Gene expression of fructosamine 3 kinase in patients with colorectal cancer

Oncology

Volumn 73, Issue 1-2, 2008, Pages 72-75

  Caruso, Maria Gabriella ^a   Notarnicola, Maria ^a   Altomare, Donato Francesco ^b   Misciagna, Giovanni ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Colorectal cancer; Fructosamine 3 kinase; Gene expression; Glycation

Indexed keywords

FRUCTOSAMINE 3 KINASE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER THERAPY; CANCER TISSUE; COLORECTAL CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR LOCALIZATION;

AGED; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 41549140653     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000120631     Document Type: Article

References (23)

1. Fortpied J, Maliekal P, Vertommen D, Van Schaftingen E: Magnesium-dependent phosphatase-1 is a protein-fructosamine-6-phosphatase potentially involved in glycation repair. J Biol Chem 2006;281:18378-18385.
2. Szwergold BS: Intrinsic toxicity of glucose, due to non-enzymatic glycation, is controlled in-vivo by deglycation systems including: FN3K-mediated deglycation of fructosamines and transglycation of aldosamines. Med Hypotheses 2005;65:337-348.
3. Delpierre G, Van Schaftingen E: Fructosamine 3-kinase, an enzyme involved in protein deglycation. Biochem Soc Trans 2003;31:1354-1357.
4. Delpierre G, Rider MH, Collard F, et al: Identification, cloning and heterologous expression of a mammalian fructosamine-3-kinase. Diabetes 2000;49:1627-1634.
5. Delpierre G, Vertommen D, Communi D, Rider H, Van Schaftingen E: Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin. J Biol Chem 2004;279:27613-27620.
6. Monnier VM: The fructosamine 3-kinase knockout mouse: a tool for testing the glycation hypothesis of intracellular protein damage in diabetes and aging. Biochem J 2006;399:e11-e13.
7. Van Schaftingen E, Delpierre G, Collard F, Fortpied J, Gemayel R, Wiame E, Veiga-da-Cunha M: Fructosamine 3-kinase and other enzymes involved in protein deglycation. Adv Enzyme Regul 2007;47:261-269.
8. Delpierre G, Collard F, Fortpied J, Van Schaftingen E: Fructosamine-3-kinase is involved in an intracellular deglycation pathway. Biochem J 2002;365:801-808.
9. Veiga-da-Cunha M, Jacquemin P, Delpierre G, Godfraind C, Theate I, Vertommen D, Clotman F, Lemaigre F, Devuyst O, Van Schaftingen E: Increased protein glycation in fructosamine 3-kinase-deficient mice. Biochem J 2006;399:257-264.
10. Conner JR, Beisswenger PJ, Szwergold BS: The expression of the genes for fructosamine-3-kinase and fructosamine-3-kinaserelated protein appears to be constitutive and unaffected by environmental signals. Biochem Biophys Res Commun 2004;323:932-936.
11. Brownlee M: Glycation and diabetic complications. Diabetes 1994;43:836-841.
12. Misciagna, G, Logroscino G, De Michele G, Guerra V, Cisternino AM, Caruso MG, Trevisan M: Glycated apolipoprotein B and myocardial infarction. Nutr Metab Cardiovasc Dis 2007;17:6-12.
13. Misciagna G, De Michele G, Guerra V, Cisternino AM, Di Leo A, Freudenheim JL, INTEROSP Group: Serum fructosamine and colorectal adenomas. Eur J Epidemiol 2004;19:425-432.
14. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS: Atherosclerosis and cancer. Common molecular pathways of disease development and progression. Ann NY Acad Sci 2001;947:271-293.
15. Giovannucci E, Michaud D: The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007;132:2208-2225.
16. Szwergold BS, Howell S, Beisswenger PJ: Human fructosamine-3-kinase: purification, sequencing, substrate specificity and evidence of activity in vivo. Diabetes 2001;50:2139-2147.
17. McVerry BA, Fisher C, Hopp A, Huens ER: Production of pseudodiabetic renal glomerular changes in mice after repeated injections of glycosylated proteins. Lancet 1980;i:738-740.
18. Ziydeh FN, Cohen MP: Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy. Mol Cell Biochem 1993;125:19-25.
19. Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M: Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients. Med Hypotheses 2005;64:1208-1210.
20. Kuniyasu H, Chihara Y, Takahashi T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associate closely with metastasis of colorectal cancer. Oncol Rep 2003;10:445-448.
21. Sasahira T, Akama Y, Fujii K, Kuniyasu H: Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 2005;446:411-415.
22. Zill H, Gunther R, Erbersdobler HF, Folsh UR, Faist V: RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochem Biophys Res Commun 2001;288:1108-1111.
23. Kuniyasu H, Oue N, Wkikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-170.